Alejandro Ferraz Prado

Dr. Alejandro Ferraz Prado

Federal University of Para, Belém, Pará, Brazil
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 April 2021 in Biomolecules
Verified
Journal Article
Open access
PDF file
Alejandro Ferraz PradoAlejandro Ferraz Prado
Alejandro Ferraz Prado
RBRose I. M. Batista
Rose I. M. Batista
Jose Tanus-SantosJose Tanus-Santos
Jose Tanus-Santos
RGRaquel Fernanda Gerlach
Raquel Fernanda Gerlach
Various pathophysiological mechanisms have been implicated in hypertension, but those resulting in vascular dysfunction and remodeling are critical and may help to identify critical pharmacological targets. This mini-review article focuses on central mechanisms contributing to the vascular dysfunction and remodeling of hypertension, increased oxidative stress and impaired nitric oxide (NO) bioavailability, which enhance vascular matrix metalloproteinase (MMP) activity. The relationship between NO, MMP and oxidative stress culminating in the vascular alterations of hypertension is examined. While the alterations of hypertension are not fully attributable to these pathophysiological mechanisms, there is strong evidence that such mechanisms play critical roles in increasing vascular MMP expression and activity, thus resulting in abnormal degradation of extracellular matrix components, receptors, peptides, and intracellular proteins involved in the regulation of vascular function and structure. Imbalanced vascular MMP activity promotes vasoconstriction and impairs vasodilation, stimulating vascular smooth muscle cells (VSMC) to switch from contractile to synthetic phenotypes, thus facilitating cell growth or migration, which is associated with the deposition of extracellular matrix components. Finally, the protective effects of MMP inhibitors, antioxidants and drugs that enhance vascular NO activity are briefly discussed. Newly emerging therapies that address these essential mechanisms may offer significant advantages to prevent vascular remodeling in hypertensive patients.

25 July 2014 in Basic & Clinical Pharmacology & Toxicology
Verified
Journal Article
Closed access
PDF file
AAAline Azevedo
Aline Azevedo
Alejandro Ferraz PradoAlejandro Ferraz Prado
Alejandro Ferraz Prado
RARaquel C. Antonio
Raquel C. Antonio
JIJoao P. Issa
Joao P. Issa
RGRaquel Fernanda Gerlach
Raquel Fernanda Gerlach

25 July 2022 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
PGPricila Rodrigues Gonçalves
Pricila Rodrigues Gonçalves
LNLisandra Duarte Nascimento
Lisandra Duarte Nascimento
RGRaquel Fernanda Gerlach
Raquel Fernanda Gerlach
KRKeuri Eleutério Rodrigues
Keuri Eleutério Rodrigues
Alejandro Ferraz PradoAlejandro Ferraz Prado
Alejandro Ferraz Prado
Heart failure (HF) is an acute or chronic clinical syndrome that results in a decrease in cardiac output and an increase in intracardiac pressure at rest or upon exertion. The pathophysiology of HF is heterogeneous and results from an initial harmful event in the heart that promotes neurohormonal changes such as autonomic dysfunction and activation of the renin-angiotensin-aldosterone system, endothelial dysfunction, and inflammation. Cardiac remodeling occurs, which is associated with degradation and disorganized synthesis of extracellular matrix (ECM) components that are controlled by ECM metalloproteinases (MMPs). MMP-2 is part of this group of proteases, which are classified as gelatinases and are constituents of the heart. MMP-2 is considered a biomarker of patients with HF with reduced ejection fraction (HFrEF) or preserved ejection fraction (HFpEF). The role of MMP-2 in the development of cardiac injury and dysfunction has clearly been demonstrated in animal models of cardiac ischemia, transgenic models that overexpress MMP-2, and knockout models for this protease. New research to minimize cardiac structural and functional alterations using non-selective and selective inhibitors for MMP-2 demonstrates that this protease could be used as a possible pharmacological target in the treatment of HF.

26 June 2024 in Pharmacological Research
Verified
Journal Article
Open access
KRKeuri Eleutério Rodrigues
Keuri Eleutério Rodrigues
MPMaria Helena Barbosa Pontes
Maria Helena Barbosa Pontes
MCManoel Benedito Sousa Cantão
Manoel Benedito Sousa Cantão
Alejandro Ferraz PradoAlejandro Ferraz Prado
Alejandro Ferraz Prado
Heart failure (HF) is the leading cause of morbidity and mortality in cardiovascular diseases, being responsible for many hospitalizations annually. HF is considered a public health problem with significant economic and social impact, which makes searches essential for strategies that improve the ability to predict and diagnose HF. In this way, biomarkers can help in risk stratification for a more personalized approach to patients with HF. Preclinical and clinical evidence shows the participation of matrix metalloproteinase 9 (MMP-9) in the HF process. In this review, we will demonstrate the critical role that MMP-9 plays in cardiac remodeling and dysfunction. We will also show its importance as a blood biomarker in acute and chronic HF patients.

1 October 2015 in European Journal of Pharmacology
Verified
Journal Article
Closed access
LPLarissa Pernomian
Larissa Pernomian
Alejandro Ferraz PradoAlejandro Ferraz Prado
Alejandro Ferraz Prado
MGMayara S. Gomes
Mayara S. Gomes
CSCarlos H.T.P. da Silva
Carlos H.T.P. da Silva
RGRaquel F. Gerlach
Raquel F. Gerlach
AOAna M. de Oliveira
Ana M. de Oliveira

1 October 2015 in European Journal of Pharmacology
Verified
Journal Article
Closed access
JMJosimar D. Moreira
Josimar D. Moreira
LPLarissa Pernomian
Larissa Pernomian
MGMayara S. Gomes
Mayara S. Gomes
RMRafael P. Moreira
Rafael P. Moreira
Alejandro Ferraz PradoAlejandro Ferraz Prado
Alejandro Ferraz Prado
AOAna M. de Oliveira
Ana M. de Oliveira